Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Cameron grandmother calls for Maytag oven recall after her stove explodes
Recommended
WRAL Investigates: Why some veterinarians face minor charges for deadly mistakes
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cyclo Therapeutics Inc
(NQ:
CYTH
)
0.7216
UNCHANGED
Streaming Delayed Price
Updated: 3:37 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cyclo Therapeutics Inc
< Previous
1
2
3
4
Next >
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
October 21, 2024
Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience
From
Pacira BioSciences
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
September 06, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
September 05, 2024
From
Cyclo Therapeutics
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, ARCH, CYTH on Behalf of Shareholders
August 27, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
August 27, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
August 26, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, SDIG, ARCH, CYTH on Behalf of Shareholders
August 24, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to Shareholders
August 22, 2024
From
Halper Sadeh LLC
Via
Business Wire
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
August 22, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
August 22, 2024
From
Rafael Holdings, Inc.; Cyclo Therapeutics
Via
GlobeNewswire
Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 15, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office
July 29, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
June 25, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
June 14, 2024
Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
May 30, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 16, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 18, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
March 14, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
March 13, 2024
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
January 29, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
December 27, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
December 18, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
December 14, 2023
Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
November 21, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
November 15, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
October 30, 2023
Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities
From
Rafael Holdings, Inc.
Via
GlobeNewswire
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million
October 23, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
October 05, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Intercept Pharmaceuticals, Inc. (Nasdaq – ICPT), Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasdaq –
September 26, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Splunk, Inc. (Nasdaq – SPLK), Applied Molecular Transport Inc. (Nasdaq - AMTI), NextGen Healthcare, Inc. (Nasdaq – NXGN), Computer Task Group, Incorporated (Nasdaq -
September 21, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.